Company news

Fortress Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

September 19, 2024

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

September 15, 2024

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

August 12, 2024

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

July 24, 2024

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

July 4, 2024

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 14, 2024

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

May 13, 2024

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

April 28, 2024

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

March 27, 2024

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

March 3, 2024

Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 2, 2024

Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 28, 2023

Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.

December 5, 2023

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 13, 2023

Fortress Biotech Announces Closing of $10.0 Million Public Offering

November 13, 2023

Fortress Biotech Announces Pricing of $10.0 Million Public Offering

November 9, 2023

Fortress Biotech Announces Launch of Proposed Public Offering

November 8, 2023

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1

October 15, 2023

Fortress Biotech Announces Reverse Stock Split

October 8, 2023

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

August 13, 2023

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program

June 14, 2023

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 14, 2023

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

April 23, 2023

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

March 29, 2023

Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

February 7, 2023

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

December 18, 2022

Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 13, 2022

Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

October 4, 2022

Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 10, 2022

Fortress Biotech Appoints David Jin as Chief Financial Officer

July 21, 2022

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

May 30, 2022

Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 11, 2022

Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

March 31, 2022

Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights

March 27, 2022

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting

March 20, 2022

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

March 2, 2022

Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21

December 20, 2021

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

December 15, 2021

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease

December 6, 2021

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

November 14, 2021

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

October 12, 2021

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

October 5, 2021

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

September 28, 2021

Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights

August 15, 2021

Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

May 15, 2021

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

May 9, 2021

Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights

March 30, 2021

Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®

February 25, 2021

Avenue Therapeutics Provides Regulatory Update for IV Tramadol

December 16, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 24 decks. Every deck is listed under its year.